Journal
BIOCONJUGATE CHEMISTRY
Volume 26, Issue 11, Pages 2243-2248Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.bioconjchem.5b00244
Keywords
-
Categories
Funding
- National Institutes of Health [U01 CA174844, R01 CA181258]
- Lymphoma Research Foundation
- Klorfine Foundation
Ask authors/readers for more resources
Site-specific conjugation technologies enable the production of homogeneous antibody drug conjugates (ADCs) with improved therapeutic indices compared to conventional ADCs. However, current site-specific conjugation methods can only attach one type of drug to a single antibody. Given the emergence of acquired resistance to current ADCs, arming single antibodies with different drugs may provide an attractive option in the development of next-generation ADCs. Here, we describe a site-specific dual conjugation strategy as a platform for dual warhead ADCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available